KIT and melanoma: While KIT may not represent a reliable primary therapeutic target in melanoma due to it being mutated in a small fraction of lesions [1,3], its relevance as a target may be envisaged in the context of acquired drug resistance of BRAF-mutant melanoma treated with targeted therapies.